Study of AL8326 for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You have been diagnosed with small cell lung cancer that has come back or spread after at least two prior treatments.
- You need to have at least one tumor that can be measured on a scan.
- Your overall health should be fairly good (able to do light activities like housework or walking).
- Your kidney, liver, and blood counts must be within a certain range.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests how well two study drugs (and a combination of them) work in people with extensive-stage small cell lung cancer. It’s mainly for patients whose cancer has come back or who couldn’t tolerate at least some standard treatments, and it aims to see if treatment can shrink tumors and be tolerable.
This Phase 2 study tests a new treatment for people with small cell lung cancer, non-small cell lung cancer, or kidney cancer after they have finished their first main treatment. It may help shrink tumors or control the cancer further.
This trial tests a new combination of two drugs (AL8326 and Toripalimab) for people with advanced solid tumors that have stopped responding to standard treatments or have no other options. The goal is to see if the combination is safe and shrinks tumors.
This trial is testing a new drug called AL58805 for people with advanced cancers that have not improved with standard treatments. The goal is to see if the drug is safe and can help shrink tumors.
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
Hear when a new Small Cell Lung Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.